Table 2.

Composition of different designed imatinib transfersomal formulations and their observed responses

Formulations	EA type	P	R	Particle size (nm)	PDI	Zeta potential (mV)	Encapsulation efficiency (%)	Release efficiency (%)
P25R4S80	Span 80	25	4	133.91 ± 2.11	0.42 ± 0.02	-3.84 ± 0.13	69.65 ± 0.85	57.82 ± 1.27
P37.5R10T80	Tween 80	37.5	10	127.43 ± 3.46	0.48 ± 0.03	-15.13 ± 0.91	96.03 ± 1.64	83.26 ± 2.14
P50R7S80	Span 80	50	7	146.19 ± 1.64	0.28 ± 0.01	-4.13 ± 0.21	92.16 ± 1.33	50.83 ± 2.25
P50R10S80	Span 80	50	10	151.18 ± 3.71	0.29 ± 0.02	-10.90 ± 0.47	91.79 ± 2.12	53.55 ± 3.42
P50R4S20	Span 20	50	4	334.45 ± 5.96	0.48 ± 0.02	-3.45 ± 0.36	91.12 ± 0.79	59.93 ± 1.09
P37.5R7S80	Span 80	37.5	7	158.14 ± 2.59	0.25 ± 0.01	-2.67 ± 0.15	98.88 ± 0.34	46.65 ± 3.83
P37.5R10S20	Span 20	37.5	10	101.59 ± 1.60	0.29 ± 0.02	-1.82 ± 0.04	82.68 ± 2.80	74.58 ± 3.76
P25R7S80	Span 80	25	7	117.46 ± 2.65	0.42 ± 0.02	-1.12 ± 0.01	90.71 ± 2.74	56.67 ± 3.48
P50R7T80	Tween 80	50	7	99.14 ± 0.98	0.41 ± 0.04	-5.55 ± 0.37	92.82 ± 1.76	67.30 ± 2.65
P37.5R4T80	Tween 80	37.5	4	110.26 ± 1.96	0.41 ± 0.03	-21.33 ± 1.03	96.59 ± 1.00	67.89 ± 2.63
P50R4S80	Span 80	50	4	134.32 ± 2.12	0.27 ± 0.01	-4.53 ± 0.22	75.94 ± 3.10	48.99 ± 2.53
P25R10S80	Span 80	25	10	123.38 ± 2.19	0.41 ± 0.03	-17.41 ± 0.86	96.98 ± 0.20	78.14 ± 1.82
P37.5R10S20	Span 20	37.5	10	105.34 ± 2.53	0.29 ± 0.03	-2.70 ± 0.02	85.59 ± 0.81	72.42 ± 2.46
P37.5R7S80	Span 80	37.5	7	96.46 ± 1.80	0.32 ± 0.04	-1.85 ± 0.06	94.24 ± 2.33	49.31 ± 2.36
P25R7T80	Tween 80	25	7	145.82 ± 2.24	0.36 ± 0.04	-19.20 ± 1.10	93.28 ± 1.66	60.42 ± 2.78
P25R4S20	Span 20	25	4	304.70 ± 4.88	0.54 ± 0.05	-3.96 ± 0.31	89.43 ± 2.45	67.31 ± 4.19

P: Lecithin content (mg); R: Lecithin/EA ratio (w/w); S80: Span 80; T80: Tween 80.